Animal (Multi-Species) — CDMO Services

Scope: Veterinary vaccines and immunobiologics (inactivated, live-attenuated, subunit, recombinant proteins, non-replicating vectors), therapeutic proteins and mAbs for companion and production animals, enzymes and probiotics, veterinary drug products and diagnostics reagents. Multi-species development and manufacturing covering canine, feline, equine, bovine, ovine, caprine, swine, poultry, aquaculture, camelids, and exotics—from process design through GMP/regulated release in a unified digital QMS (ALCOA+).

Animal-health programs are a different problem set. Doses are delivered in barns, kennels, feedlots, hatcheries, and on vessels at sea. Economics matter as much as potency; ruggedness matters as much as elegance. Regulators differ (USDA-CVB for biologics; FDA-CVM for drugs; EMA-CVMP/Ph. Eur. in the EU; CFIA/Health Canada in Canada), and field use imposes constraints human programs rarely see (multi-dose vials, spray or drinking-water delivery, immersion baths for fish, in-feed applications). We build for that reality from day one: define what must be true at the point of care, then design process, formulation, packaging, and documentation to make it repeatable—and inspectable.

Why teams choose MycoVista for multi-species work

Context. Success in veterinary manufacturing comes from aligning biology, process physics, cost, and logistics across species and delivery modes. We approach it like an engineering program with clear tradeoffs, operator-holdable ranges, and artifacts reviewers can follow.

• End-to-end execution across modalities. Vaccines and immunobiologics, therapeutic proteins/mAbs, enzymes and probiotics, small-molecule veterinary drugs, and diagnostic reagents—developed, manufactured, tested, and filled under one spine of methods and records in two synchronized facilities.
• Species-aware design. Routes (SC/IM/IV/intramammary/oral/in-water/immersion/spray), dose volumes, excipient tolerances, viscosity and syringeability, preservative use for multi-dose vials, and device compatibility are considered at the outset—not after scale-up.
• Regulatory literacy. We map your product to the right path: USDA-CVB biologies (Outlines of Production, Master/Working Seeds, serial release for Purity/Safety/Potency/Sterility); FDA-CVM drugs (NADA/ANADA; 21 CFR 210/211; VICH); EU CVMP expectations and Ph. Eur. monographs; CFIA/Health Canada for Canada.
• Evidence over optimism. Acceptance criteria exist before DoE. Orthogonal analytics are used where they reduce risk. Comparability protocols are prespecified for site/scale/material changes.
• Operational calm. Oxygen transfer, shear, filter capacity, adjuvant emulsions, preservative load, and packaging survive night-shift reality. If it cannot be held by trained operators, it isn’t locked.
• Background: constraints that actually govern veterinary programs

Veterinary biologics and drugs fail late for predictable reasons: vaccine antigens that behave in lab buffers but not in oil-in-water emulsions; probiotic CFU targets that collapse after in-feed pelleting; endotoxin control assumed but not engineered; multi-dose preservative systems verified too late; species-specific tolerances (osmolality, viscosity, excipients) not respected; regulatory narratives that don’t match site practices. We address these early with a system that starts from the field and works backward to the reactor and the batch record.

Program spine: QTPP → CQAs → CPPs

QTPP (what must be true at use): species and route (e.g., canine SC; poultry spray; aquaculture immersion), dose volume and frequency, presentation (10-, 50-, 100-dose vial; sachet; PFS), potency at release and over shelf life, acceptable residuals (endotoxin for parenterals, solvents/detergents where applicable), purity and antigen content, preservative system (if multi-dose), particulate limits, and storage/shipping conditions.

CQAs (what we will measure): identity (antigen/protein/strain), potency (in vitro, in vivo where required by authority), purity and size variants, residual DNA/protein/endotoxin/antifoam or process aids, CFU/spore counts for probiotics, enzyme activity, adjuvant droplet size or emulsion stability (for adjuvanted vaccines), sterility/bioburden as applicable, preservative content, pH/osmolality/viscosity, and stability.

CPPs (what we can control): host/construct and seed systems, feed/induction and environmental setpoints, shear and oxygen transfer envelopes, lysis and clarification chemistry (or secretion settings), capture loading/residence times, polishing gradients/ionic strength, adjuvant emulsion parameters (phase ratios, shear, temperature), UF/DF recipes, preservative levels, filtration ∆P/T, and fill settings (line speed, nozzle depth, nitrogen overlays).

Deliverable: a control strategy that ties QTPP→CQA→CPP to specific methods, unit operations, and batch-record entries.

Species & delivery overview

Companion animals (canine/feline). SC/IM volumes are modest; viscosity and injection comfort matter; multi-dose vials common. Endotoxin limits and visible particulate controls are enforced. Palatability and excipient tolerance matter for oral forms.

Equine. Larger injection volumes possible; intranasal options for certain vaccines; device and needle gauge compatibility matter; storage and field stability are stressed (trailers, barns).

Ruminants (bovine/ovine/caprine). Intramammary presentations for mastitis programs; in-feed and oral drenches; robustness against on-farm handling; packaging that survives chillers and warm barns.

Swine. Mass vaccination logistics (needles, applicators), in-feed or in-water administration, barn environmental variability; preservative systems must hold up across multi-dose vials.

Poultry. Hatchery-grade stability; spray or drinking-water delivery; droplet size and chlorine tolerance matter; high-throughput batching and labeling for very large lots.

Aquaculture. Immersion baths or in-feed; temperature and salinity windows; very tight control of potency over exposure time; container and labeling suited to wet processing.

Camelids & exotics/zoo. Small populations; tailored dose/volume; species-specific excipient tolerance; documentation that travels across institutions.

Modalities & platforms

Vaccines & immunobiologics

• Antigen production. Mammalian (CHO/HEK) or microbial/yeast/fungal as biology dictates; BEVS for rapid recombinant antigens.
• Adjuvants. Alum, saponin-based, and oil-in-water systems where justified; we define droplet size, phase ratios, shear/temperature windows, and hold-time limits; preservative strategies for multi-dose vials validated.
• Delivery. SC/IM vials (10- to 100-dose), hatchery spray or drinking-water concentrates, immersion formulations for fish; labels and IFUs aligned to practice.
• Potency. In vitro correlates (e.g., antigen content, inhibition/neutralization surrogates) and in vivo potency models as required by authority (planned with sponsors and CROs).

Therapeutic proteins & veterinary mAbs

• Use cases. Anti-inflammatory and anti-infective targets, antitoxins, and supportive biologics.
• Design. Mammalian CLD with documented clonality; perfusion or fed-batch; Protein A capture and orthogonal polishing; excipient strategies tuned to animal tolerability and device feasibility.

Enzymes & probiotics

• Enzymes. Microbial expression with activity-first design; downstream clears residuals and protects activity; formulations for liquid or lyo, often for oral use or feed inclusion.
• Probiotics. Strain identity verification, CFU/spore counts, desiccation and heat tolerance; coating or encapsulation for pelleting or in-feed; stability under barn logistics.

Veterinary drug products

• Forms. Oral paste/suspension/tablet, intramammary ointment, topical; process chemistry and DP support where part of an integrated program with biologics.

Upstream development

We design microbial and mammalian processes with headroom, not “best day” settings. For microbial, carbon-limited fed-batch prevents overflow metabolism; Pichia induction envelopes include explosion-safety logic and oxygen enrichment plans. For mammalian, feed/temperature/osmolality strategies respect DSP realities. Secretion programs (yeast/fungi Bacillus/Corynebacterium) are preferred when downstream wins; inclusion-body routes are used only when refold can be engineered with activity as the scoreboard.

PAT. Off-gas, capacitance, and spectroscopic signals are calibrated to reference assays so each shift is decisional.

Downstream (clarification → capture → polish) built for field constraints

• Clarification. Centrifugation and depth filtration with measured pressure–throughput curves; flocculation/conditioning only when it pays in validation. For inclusion bodies, lysis strategies avoid capture poisoning and control endotoxin.
• Capture. AEX/CEX/HIC/mixed-mode chosen by impurity maps; affinity when lifecycle cost and cleaning allow; multi-column when it materially reduces COGs.
• Polishing. Ion exchange for charge noise; HIC for misfolded/aggregates; mixed-mode where single mechanisms fail; membrane options when SEC won’t scale.
• UF/DF & formulation setup. MWCO by hydrodynamic radius; staged diafiltration to preserve activity; adjuvant compatibility and preservative stability verified on real intermediates.

Formulation & presentation for field use

• Multi-dose vials. Preservative systems validated for antimicrobial effectiveness and compatibility with antigens; stopper/closure integrity with multiple punctures; label clarity for barn workflows.
• Spray and in-water concentrates (poultry). Droplet size control, chlorine/metal tolerance, and stability during dilution; instructions and dosing devices matched to hatchery practice.
• Immersion (aquaculture). Buffer and osmolality that protect potency and gill health; container volumes and closures designed for wet processing.
• Companion-animal injections. Viscosity and syringeability tuned; comfort and needle gauge considered; sterile filtration feasibility proved early.
• Oral/in-feed probiotics and enzymes. CFU/spore survival through pelleting or pasteurization; coating/encapsulation where needed; palatability and excipient tolerability.

Analytics that answer regulators and practitioners

• Identity & purity. Intact mass/peptide mapping; CE-SDS, SEC-MALS; glycan profiling where risk warrants; antigen content assays with defined acceptance criteria.
• Potency. In vitro correlates (e.g., HI/neutralization surrogates, enzyme activity) and in vivo potency per authority; bridging plans documented.
• Residuals & safety. Endotoxin for parenterals; host-cell proteins/DNA; residual lysis agents/precipitants; antibiotic carryover (if used); sterility/bioburden as applicable; preservative content and antimicrobial effectiveness for multi-dose vials.
• Probiotics. Identity by genomic methods, CFU/spore counts by conditions relevant to use, contaminants panel; stability under feed or water conditions.
• Stability. Real and accelerated conditions reflecting barns, hatcheries, and transport; stress studies (heat, agitation, freeze-thaw, light) to map failure modes; label storage justified by data.

Lifecycle. Methods move through development → transfer (dual hubs) → qualification/validation with OOS/OOT governance and change control.

Regulatory & QMS posture (country-specific without getting lost)

• US (biologics). USDA-CVB pathway: Outlines of Production; Master/Working Seed systems; serial release for Purity, Safety, Potency, Sterility as product-appropriate; facility and process inspections under 9 CFR.
• US (drugs). FDA-CVM (NADA/ANADA); 21 CFR 210/211 cGMP; VICH guidance alignment.
• EU. EMA-CVMP expectations; EU GMP; relevant Ph. Eur. monographs for immunological veterinary medicinal products; country-specific batch controls where required.
• Canada. CFIA (veterinary biologics) and Health Canada VDD (veterinary drugs).

We draft CMC and quality sections from actual methods and data. Comparability is prespecified for changes in site, scale, or materials. Deviations/CAPA and EM/utilities trends live in the same digital QMS across hubs.

Facilities & biosecurity

• Suites. ISO 8/7 cleanrooms, positive cascades, unidirectional flows; BSL-2 where required for biologics; higher-containment work via qualified partners when indicated by pathogen class.
• Upstream. Mammalian single-use 50 L & 250 L GMP suites; microbial/fungal bench → pilot → up to 50,000 L stainless (qualified programs).
• Downstream. Pilot to GMP chromatography and TFF skids; viral filtration capability where applicable; recipe control and qualified sensors.
• Fill–finish. Vials (single and multi-dose), PFS, spray/in-water concentrates; isolator/RABS lines; lyophilization where justified; CCIT platforms; automated/manual inspection.
• Digital backbone. Validated CDS/LIMS/ELN and eBMR/eBR with audit trails, access control, and versioning—ALCOA+ by design.

Validation & PPQ readiness

Design spaces become recipes with interlocks and alarms. Cleaning validation uses defensible MACO/PDE logic. Media fills/process simulations represent real interventions and holds. Hold-time studies prevent improvised practices. Resin/membrane lifecycle tracking and stocking plans reflect campaign risk.

Program Onboarding (first 30 days)

1. Control strategy draft mapping species/route QTPP → CQAs (potency, purity, endotoxin/residuals, preservative where relevant, stability) → CPPs (upstream settings, capture/polish windows, adjuvant/UF-DF parameters, filtration, DP presentation).
2. DoE plan for upstream (feed/induction/OTR), downstream (clarification/capture/polish), and, if applicable, adjuvant emulsion and preservative validation; analytical lifecycle and, where required, in vivo potency bridging outline.
3. Gantt & risk register with gates to USDA-CVB serial release or FDA-CVM submissions (as applicable); draft label/pack/ship plan that matches species and route.

We request your current data (antigen or strain, target species and route, dose goals, early stability or field feedback) and return a written plan with dates and pass criteria.

Indicative timelines

• Feasibility (2–6 weeks). Host/route choice; early expression or antigen prep; initial clarification and capture maps; adjuvant and preservative hypotheses; potency assay handshake.
• Development (2–4 months). Upstream DoE; capture/polish limits; UF/DF and formulation; adjuvant droplet size and stability; preservative effectiveness (multi-dose); analytics qualification; stability bins aligned to storage.
• Engineering runs. Scale-similar hydrodynamics; mass balance and trending; filtration feasibility; label and packaging drafts matched to barns/hatcheries/boats.
• Lock. Process description with CPP ranges; validation plans; comparability (if changes); USDA-CVB or FDA-CVM/EMA-aligned documentation set.

We state gates and pass criteria; species biology and field constraints determine pace.

Tech transfer & rescue

We stabilize first, then optimize. Document triage covers methods, deviations, EM/utilities, release/stability, adjuvant and preservative performance, resin/filter lifecycles, and in vivo potency history where applicable. Gap mapping prioritizes oxygen transfer, filter trains, adjuvant emulsions, preservative systems, and field-relevant stability. Stabilize → optimize → re-lock with comparability for any change; lifecycle files updated.

Deliverables

• Control strategy and process description with design space and CPP ranges.
• Seed/Bank dossiers (as applicable) and identity packages.
• DSP package (clarification/capture/polish limits; UF/DF recipe; adjuvant and preservative validation).
• Analytics (methods; transfer; qualification/validation; trending; in vivo potency plans where required).
• Stability protocols/data with defendable storage and shipping guidance.
• Label/pack/ship plan tailored to species and route.
• Batch records (eBMR/eBR) and regulatory text for USDA-CVB, FDA-CVM, EMA-CVMP, or CFIA/Health Canada submissions.

Frequently asked

Do you support USDA-CVB biologics?

Yes—Outlines of Production, Master/Working Seeds, serial release (Purity/Safety/Potency/Sterility), and inspections under 9 CFR are planned into the program.

Multi-dose preservatives—when do you validate?

Early. Antimicrobial effectiveness and compatibility with antigens are tested during development, not after scale-up.

Poultry spray or drinking-water delivery?

Yes—droplet size, chlorine/metal tolerance, and stability during dilution are engineered and verified.

Aquaculture immersion?

Yes—buffers/osmolality designed for fish health; potency over immersion time measured; container volumes fitted to wet processing.

Probiotic CFU collapse after pelleting—can you prevent it?

Usually—strain selection, coating/encapsulation, and heat/moisture profiles are adjusted; we measure pre- and post-pellet survival.

Endotoxin control for parenterals?

Designed end-to-end—USP/DSP controls plus release testing; not a last-minute check.

Summary

Multi-species work is practical engineering with regulatory discipline. We start at the point of care, define what must be true, and then build process, formulation, packaging, and records that make it reliable at scale. If you want a concrete plan for your species, route, and dose, send current data and we’ll return a design space, acceptance criteria, and a documented path to regulated release.

Start Program Onboarding → Share species, route, dose goals, presentation, and current data. We’ll return a control strategy, study plan, and a documented path to GMP/regulated release.

Email our team today at info@mycovistabiotech.com